|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-11
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The effect of imatinib discontinuation on progression-free survival and overall survival in long-lasting responders with advanced gastrointestinal stromal tumours (GIST) is unknown. We assessed treatment interruption in patients with non-progressive disease according to the Response Evaluation Criteria In Solid Tumors criteria after 3 years of imatinib in a randomised trial.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:AdenisAntoineA,
pubmed-author:BertucciFrançoisF,
pubmed-author:BlayJean-YvesJY,
pubmed-author:BuiBinh NguyenBN,
pubmed-author:ChabaudSylvieS,
pubmed-author:ChevreauChristineC,
pubmed-author:CioffiAngelaA,
pubmed-author:CupissolDidierD,
pubmed-author:DuffaudFlorenceF,
pubmed-author:EmileJean-FrançoisJF,
pubmed-author:French Sarcoma Group,
pubmed-author:Le CesneAxelA,
pubmed-author:PérolDavidD,
pubmed-author:Ray-CoquardIsabelleI,
pubmed-author:RiosMariaM
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
942-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20864406-Adult,
pubmed-meshheading:20864406-Aged,
pubmed-meshheading:20864406-Aged, 80 and over,
pubmed-meshheading:20864406-Antineoplastic Agents,
pubmed-meshheading:20864406-Disease Progression,
pubmed-meshheading:20864406-Disease-Free Survival,
pubmed-meshheading:20864406-Drug Administration Schedule,
pubmed-meshheading:20864406-Female,
pubmed-meshheading:20864406-France,
pubmed-meshheading:20864406-Gastrointestinal Neoplasms,
pubmed-meshheading:20864406-Humans,
pubmed-meshheading:20864406-Kaplan-Meier Estimate,
pubmed-meshheading:20864406-Male,
pubmed-meshheading:20864406-Middle Aged,
pubmed-meshheading:20864406-Neoplasm, Residual,
pubmed-meshheading:20864406-Piperazines,
pubmed-meshheading:20864406-Protein Kinase Inhibitors,
pubmed-meshheading:20864406-Pyrimidines,
pubmed-meshheading:20864406-Risk Assessment,
pubmed-meshheading:20864406-Risk Factors,
pubmed-meshheading:20864406-Time Factors,
pubmed-meshheading:20864406-Tomography, X-Ray Computed,
pubmed-meshheading:20864406-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
|
|
pubmed:affiliation |
Institut Gustave Roussy, Villejuif, France. lecesne@igr.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
